RCUS NYSE Pharmaceutical Preparations Financials FY2016βFY2025
Arcus Biosciences, Inc. had $247M of revenue in fiscal 2025, down 4.3% on the year before. Over five years, revenue changed +25.9% a year on average.
Last close Β· Oct 23, 2026
$18.54
4.2%Hi! I read Arcus Biosciences, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β4.3%
No. Sales fell 4.3% last year.
Does it make a profit?
β142.9%
No. It lost money last year.
Does profit turn into cash?
β196.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
0 / 8
Weak. It passes 0 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Arcus Biosciences, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
February 24, 2027
Wednesday Β· in 121 days
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Oct 21, 2026 | Period ended Sep 30, 2026 | After the market closes | 8-K β |
| Aug 5, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 5, 2026 | Q1 '26 | After the market closes | 8-K β |
| Feb 25, 2026 | Q4 '25 | After the market closes | 8-K β |
| Oct 28, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 6, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 6, 2025 | Q1 '25 | After the market closes | 8-K β |
| Feb 15, 2025 | Q4 '24 | Time not announced | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Arcus Biosciences, Inc. had $247M of revenue in fiscal 2025, down 4.3% on the year before. Over five years, revenue changed +25.9% a year on average. Its operating margin was β156.3%, down 28.4Β pts: of every 100 in sales, about β156 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Arcus Biosciences, Inc. lost $353M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$484M in fiscal 2025, β196.0% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Arcus Biosciences, Inc. has $882M more cash than debt.
Cash, debt and the ratios that show how comfortably Arcus Biosciences, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $499M | $1.0B | $759M | $978M | $981M |
| Debt incl. finance leases | β | β | $0.0M | $48.0M | $99.0M |
| Debt / equity | β | β | 0.0x | 0.1x | 0.2x |
| Interest coverage | β | β140.0x | β170.0x | β82.5x | β48.3x |
| Current ratio | 7.6x | 5.5x | 4.5x | 4.5x | 4.4x |
| Quick ratio | 7.6x | 5.5x | 4.5x | 4.5x | 4.4x |
| Total assets | $1.6B | $1.3B | $1.1B | $1.2B | $1.1B |
| Total liabilities | $750M | $688M | $633M | $665M | $508M |
| Shareholders' equity | $842M | $657M | $462M | $485M | $631M |
| Net debt (β = net cash) | β | β | β$759M | β$930M | β$882M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Arcus Biosciences, Inc. passes 0 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | 4 / 7 | 2 / 7 | 4 / 7 | 4 / 7 | 3 / 7 | 2 / 7 | 3 / 8 | 0 / 8 |
| Accruals ratio | β | β14.7% | β2.8% | β4.7% | β48.0% | 26.1% | β48.0% | β0.1% | β10.1% | 11.3% |
| Altman Z'' | β | 0.44 | 9.15 | 3.65 | 4.70 | 5.36 | 2.55 | 0.03 | 0.13 | β0.75 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | β | $1.4M | $8.4M | $15.0M | $78.0M | $383M | $112M | $117M | $258M | $247M |
| Research and development | $14.2M | $47.2M | $49.6M | $78.5M | $159M | $257M | $288M | $340M | $448M | $523M |
| Operating income | β$18.2M | β$53.4M | β$54.9M | β$88.7M | β$124M | $54.0M | β$280M | β$340M | β$330M | β$386M |
| Interest expense | β | β | β | β | β | β | $2.0M | $2.0M | $4.0M | $8.0M |
| Pretax income | β | β | β | β$84.7M | β$123M | $55.0M | β$266M | β$301M | β$282M | β$353M |
| Income tax | β | β | β | β | β | $2.0M | $1.0M | $6.0M | $1.0M | $0.0M |
| Net income | β$18.0M | β$53.1M | β$49.6M | β$84.7M | β$123M | $53.0M | β$267M | β$307M | β$283M | β$353M |
| Diluted EPS | β$20.80 | β$29.03 | β$1.43 | β$1.93 | β$2.24 | $0.71 | β$3.71 | β$4.15 | β$3.14 | β$3.29 |
| Diluted shares | 0.00B | 0.00B | 0.03B | 0.04B | 0.05B | 0.07B | 0.07B | 0.07B | 0.09B | 0.11B |
| Cash flow | ||||||||||
| Cash from operations | β$12.9M | β$25.1M | β$43.0M | β$73.5M | $111M | β$256M | $438M | β$306M | β$170M | β$482M |
| Capital expenditure | $4.1M | $5.5M | $3.7M | $1.9M | $3.0M | $26.0M | $6.0M | $24.0M | $6.0M | $2.0M |
| Free cash flow | β$17.0M | β$30.6M | β$46.7M | β$75.4M | $108M | β$282M | $432M | β$330M | β$176M | β$484M |
| Depreciation and amortization | $1.3M | $2.6M | $3.7M | $3.6M | $3.0M | $4.0M | $6.0M | $8.0M | $10.0M | $10.0M |
| Stock-based compensation | $0.1M | $0.5M | $3.9M | $9.0M | $22.0M | $55.0M | $65.0M | $73.0M | $76.0M | $60.0M |
| Share buybacks | β | β | $0.0M | $0.1M | β | β | β | β | β | β |
| Dividends and buybacks | β | β | $0.0M | $0.1M | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $65.2M | $98.4M | $71.1M | $57.9M | $729M | $499M | $1.0B | $759M | $978M | $981M |
| Total debt | β | β | β | β | β | β | β | $0.0M | $48.0M | $99.0M |
| Current assets | β | $177M | $259M | $193M | $736M | $1.3B | $1.1B | $831M | $1.0B | $1.0B |
| Current liabilities | β | $12.7M | $16.9M | $22.7M | $122M | $166M | $193M | $184M | $226M | $231M |
| Property and equipment, net | β | $11.2M | $11.1M | $9.3M | $10.8M | $32.0M | $35.0M | $51.0M | $47.0M | $40.0M |
| Total assets | β | $190M | $275M | $203M | $772M | $1.6B | $1.3B | $1.1B | $1.2B | $1.1B |
| Total liabilities | β | $36.6M | $40.0M | $39.3M | $270M | $750M | $688M | $633M | $665M | $508M |
| Preferred stock | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β |
| Shareholders' equity | β$20.0M | β$72.3M | $235M | $164M | $502M | $842M | $657M | $462M | $485M | $631M |
| Margins | ||||||||||
| Operating margin | β | β3,782.1% | β656.8% | β591.4% | β159.0% | 14.1% | β250.0% | β290.6% | β127.9% | β156.3% |
| EBITDA margin | β | β3,597.2% | β612.9% | β567.5% | β155.1% | 15.1% | β244.6% | β283.8% | β124.0% | β152.2% |
| Net margin | β | β3,756.7% | β593.7% | β564.7% | β157.7% | 13.8% | β238.4% | β262.4% | β109.7% | β142.9% |
| FCF margin | β | β2,163.7% | β559.5% | β502.6% | 138.5% | β73.6% | 385.7% | β282.1% | β68.2% | β196.0% |
| Returns | ||||||||||
| Return on capital employed | β | β30.1% | β21.3% | β49.2% | β19.1% | 3.8% | β24.3% | β37.3% | β35.7% | β42.5% |
| Return on equity | β | β | β61.0% | β42.5% | β36.9% | 7.9% | β35.6% | β54.9% | β59.8% | β63.3% |
| Return on assets | β | β27.9% | β21.3% | β35.4% | β25.2% | 4.5% | β18.2% | β25.2% | β25.2% | β30.8% |
| Return on tangible equity | β | β | β21.1% | β51.7% | β24.5% | 6.3% | β40.6% | β66.5% | β58.4% | β55.9% |
| Growth | ||||||||||
| Revenue growth | β | β | 491.2% | 79.6% | 420.0% | 391.0% | β70.8% | 4.5% | 120.5% | β4.3% |
| Net income growth | β | β | β | β | β | β | β603.8% | β | β | β |
| EPS growth | β | β | β | β | β | β | β622.5% | β | β | β |
| FCF growth | β | β | β | β | β | β361.1% | β | β176.4% | β | β |
| Share count change | β | 111.6% | 1,793.5% | 26.6% | 25.0% | 35.0% | β2.7% | 2.8% | 21.8% | 19.2% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | β | β | β | 0.0x | 0.1x | 0.2x |
| Interest coverage | β | β | β | β | β | β | β140.0x | β170.0x | β82.5x | β48.3x |
| Current ratio | β | 13.9x | 15.3x | 8.5x | 6.0x | 7.6x | 5.5x | 4.5x | 4.5x | 4.4x |
| Quick ratio | β | 13.9x | 15.3x | 8.5x | 6.0x | 7.6x | 5.5x | 4.5x | 4.5x | 4.4x |
| Capital allocation | ||||||||||
| Capex / revenue | β | 390.2% | 44.8% | 12.8% | 3.8% | 6.8% | 5.4% | 20.5% | 2.3% | 0.8% |
| Stock comp / revenue | β | 35.0% | 46.4% | 59.9% | 28.2% | 14.4% | 58.0% | 62.4% | 29.5% | 24.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | 4.0 | 2.0 | 4.0 | 4.0 | 3.0 | 2.0 | 3.0 | 0.0 |
| Altman Z'' | β | 0.4 | 9.1 | 3.6 | 4.7 | 5.4 | 2.6 | 0.0 | 0.1 | β0.8 |
| Accruals ratio | β | β14.7% | β2.8% | β4.7% | β48.0% | 26.1% | β48.0% | β0.1% | β10.1% | 11.3% |
Source: SEC EDGAR XBRL filings (CIK 0001724521). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
